Show simple item record

dc.contributor.authorCaro Salazar, Carlos
dc.contributor.authorGámez Márquez, Francisco
dc.date.accessioned2021-04-14T06:43:54Z
dc.date.available2021-04-14T06:43:54Z
dc.date.issued2021
dc.identifier.citationCaro, C.; Gámez, F.; Quaresma, P.; Páez-Muñoz, J.M.; Domínguez, A.; Pearson, J.R.; Pernía Leal, M.; Beltrán, A.M.; FernandezAfonso, Y.; De la Fuente, J.M.; et al. Fe3O4-Au Core-Shell Nanoparticles as a Multimodal Platform for In Vivo Imaging and Focused Photothermal Therapy. Pharmaceutics 2021, 13, 416. https://doi.org/10.3390/ pharmaceutics13030416es_ES
dc.identifier.urihttp://hdl.handle.net/10481/67934
dc.description.abstractIn this study, we report the synthesis of gold-coated iron oxide nanoparticles capped with polyvinylpyrrolidone (Fe@Au NPs). The as-synthesized nanoparticles (NPs) exhibited good stability in aqueous media and excellent features as contrast agents (CA) for both magnetic resonance imaging (MRI) and X-ray computed tomography (CT). Additionally, due to the presence of the local surface plasmon resonances of gold, the NPs showed exploitable “light-to-heat” conversion ability in the near-infrared (NIR) region, a key attribute for effective photothermal therapies (PTT). In vitro experiments revealed biocompatibility as well as excellent efficiency in killing glioblastoma cells via PTT. The in vivo nontoxicity of the NPs was demonstrated using zebrafish embryos as an intermediate step between cells and rodent models. To warrant that an effective therapeutic dose was achieved inside the tumor, both intratumoral and intravenous routes were screened in rodent models by MRI and CT. The pharmacokinetics and biodistribution confirmed the multimodal imaging CA capabilities of the Fe@AuNPs and revealed constraints of the intravenous route for tumor targeting, dictating intratumoral administration for therapeutic applications. Finally, Fe@Au NPs were successfully used for an in vivo proof of concept of imaging-guided focused PTT against glioblastoma multiforme in a mouse model.es_ES
dc.description.sponsorshipSpanish Ministry of Economy, Industry and Competitiveness (CTQ2017-86655-R and BIO2017-84246-C2-1-R)es_ES
dc.description.sponsorshipFondo Social de la DGA (grupos DGA) and by the Regional Ministry of Health of Andalusia (OH-0026-2018).es_ES
dc.description.sponsorshipAssociate Laboratory for Green Chemistry—LAQVes_ES
dc.description.sponsorshipApplied Molecular Biosciences Unit –UCIBIOes_ES
dc.description.sponsorshipPortuguese national funds from FCT/MCTES (UIDB/04378/2020 and UIDB/50006/2020)es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectImaging-guided therapyes_ES
dc.subjectMultimodal imaginges_ES
dc.subjectContrast agentes_ES
dc.subjectMRIes_ES
dc.subjectCTes_ES
dc.titleFe3O4-Au Core-Shell Nanoparticles as a Multimodal Platform for In Vivo Imaging and Focused Photothermal Therapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/pharmaceutics13030416


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España